Physician profile

Stephen Delatte

Lafayette, LA

NPI 1245253194

$3,441.49

in general payments reported to CMS, 2019-2025

14 companies · $542 in 2025

The $542 reported for 2025 was more than what 80% of providers received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,682.73
Long Term Medical Supply Or Device Loan$326.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Revance Therapeutics, INC. $765.20 2024-2025 Daxxify
Galderma Laboratories, L.P. $627.29 2019-2024 Dysport
Abbvie INC. $385.79 2023-2025 Natrelle Saline-Filled Breast Implants, Botox
Allergan, INC. $365.17 2019-2022
Integra Lifesciences Corporation $361.28 2023-2025 Durasorb Monofilament Mesh, Integra, Integra Dermal Regeneration Template
Tepha INC $248.07 2019
Tela Bio, INC. $153.24 2024 Ovitex 2s
Davol INC. $141.34 2022
Mentor Worldwide LLC $133.88 2024-2025 Mentor Memorygel Resterilizable Gel Sizer, Artoura Breast Tissue Expander
Sientra, INC. $131.27 2022
Baxter Healthcare $39.54 2020
Getinge USA Sales, LLC $36.53 2021
Ethicon US, LLC $32.99 2023 Vistaseal
Motiva USA, LLC $19.90 2025

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Stephen Delatte

$3,441.49

in general payments reported 2019-2025

Years
2019-2025
Top company
Revance Therapeutics, INC.
Context
The $542 reported for 2025 was more than what 80% of providers received nationally.

https://glasscript.com/doctor/146803/stephen-delatte

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.